{"id":24287,"date":"2025-12-23T16:16:26","date_gmt":"2025-12-23T16:16:26","guid":{"rendered":"https:\/\/beonemedicines.ca\/en\/?post_type=pressreleases&#038;p=24287"},"modified":"2025-12-23T16:20:43","modified_gmt":"2025-12-23T16:20:43","slug":"health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng","status":"publish","type":"pressreleases","link":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/","title":{"rendered":"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma"},"content":{"rendered":"<!-- Copy block -->\r\n<section class=\"nav-tertiary-sec copy-block  bg-white\" >\r\n    <div class=\"container\">\r\n        <div class=\"row\">\r\n            \r\n            <div class=\"col-md-8 col-lg-9\">\r\n                \r\n                <div class=\"main-container tab-container\">                    \r\n                                                <section class=\"section anim fadeInUp \">\r\n                            <!-- <section class=\"section anim fadeInUp \" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    \r\n                                            <div><p><em>Nasopharyngeal Carcinoma is a rare and debilitating disease with<\/em>\u00a0<em>limited effective treatment options currently available to Canadian patients<\/em><\/p>\n<p><em>Approval supported by results of the RATIONALE-309 study demonstrating statistically significant improvement in progression-free survival<\/em><\/p>\n<p>&nbsp;<\/p>\n<p><strong>TORONTO, Ontario<\/strong>\u00a0\u2013 December 23, 2025 \u2013 BeOne Medicines, a global oncology company, today announced that Health Canada has granted a Notice of Compliance (NOC), approving TEVIMBRA\u00ae (tislelizumab for injection) in combination with gemcitabine and cisplatin for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC). This is the first approved indication for TEVIMBRA in Canada.<\/p>\n<p>Nasopharyngeal carcinoma is a rare form of head and neck cancer that arises in the upper part of the throat behind the nose.<sup>1<\/sup>\u00a0NPC affects a small but significant number of Canadians each year and there are considerable disparities in accessing immunotherapy as part of first-line treatment for recurrent or metastatic NPC.<sup>2<\/sup><\/p>\n<p>\u201cThis approval represents an important milestone and treatment advancement for Canadians diagnosed with nasopharyngeal carcinoma,\u201d said Dr. Desiree Hao, Head and Neck Medical Oncologist at Arthur J.E. Child Comprehensive Cancer Centre and Professor of Medicine, University of Calgary. \u201cAdult patients with recurrent or metastatic NPC have long faced limited therapeutic choices. The arrival of TEVIMBRA for Canadian NPC patients is a welcomed treatment option to help address this critical unmet need.\u201d<\/p>\n<p>The Health Canada approval of TEVIMBRA was based upon the results from RATIONALE-309 (NCT03924986), a multicentre, Phase 3 randomized, double-blind trial, in which patients received either TEVIMBRA in combination with gemcitabine plus cisplatin, or placebo in combination with gemcitabine plus cisplatin. The primary endpoint was met at the first prespecified interim analysis demonstrating that TEVIMBRA significantly prolonged progression free survival (PFS) in the intent-to-treat (ITT) population (HR 0.52 [95% CI:0.38, 0.73] p&lt;0.0001), showing a 48% reduction in the risk of disease progression or death. The median PFS in the TEVIMBRA plus chemotherapy arm was 9.2 months compared to 7.4 months in the placebo plus chemotherapy arm.<sup>3<\/sup><\/p>\n<p>TEVIMBRA plus chemotherapy was generally well tolerated.\u00a0 The most common\u00a0<strong>\u2265<\/strong>Grade 3 treatment emergent adverse events (\u2265 20%) associated with TEVIMBRA given in combination with chemotherapy were neutropenia, anemia, and leukopenia.<sup>3<\/sup><\/p>\n<p>\u201cThis Health Canada approval is an important step in making a new treatment option available to Canadian patients living with NPC,\u201d said\u00a0Kristian Stubbs, General Manager, Canada, BeOne Medicines. \u201cWe believe that no one should face this devastating disease alone and we are committed to making TEVIMBRA broadly accessible to Canadian NPC patients. We look forward to partnering with stakeholders who share a sense of urgency to improve the standard of care for NPC patients in Canada.\u201d<\/p>\n<p>TEVIMBRA is anticipated to be commercially available in the first half 2026.<\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                                <section class=\"section anim fadeInUp \">\r\n                            <!-- <section class=\"section anim fadeInUp \" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    <div class=\"sec-subheading\">\r\n                                                <h4>About Nasopharyngeal Cancer (NPC) in Canada:<\/h4>\r\n                                            <\/div>\r\n                                                                                    \r\n                                            <div><p>Nasopharyngeal cancer (NPC) is a type of head and neck cancer that starts in the nasopharynx, the upper throat passage behind the nose.<sup>1<\/sup>\u00a0NPC is often diagnosed at advanced stages due to its deep anatomical location and mild early symptoms, making early detection challenging.<sup>4<\/sup>\u00a0In Canada, NPC is considered rare and occurs at rates generally below 1 per 100,000 in non-endemic regions; however, higher incidence has been reported in certain populations, including Inuit communities in Nunavut and the Northwest Territories (~10 per 100,000).<sup>2<\/sup>\u00a0Because NPC statistics are not reported separately in Canada, it is captured within the broader head and neck cancer category, for which it is estimated 8,100 Canadians will be diagnosed and 2,200 will die in 2025.<sup>5<\/sup><\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                                <section class=\"section anim fadeInUp no-popup\">\r\n                            <!-- <section class=\"section anim fadeInUp no-popup\" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    <div class=\"sec-subheading\">\r\n                                                <h4>About TEVIMBRA (tislelizumab)<\/h4>\r\n                                            <\/div>\r\n                                                                                    \r\n                                            <div><p>Tislelizumab is a humanized immunoglobulin G4 (IgG4) variant monoclonal antibody against PD-1.\u00a0 Binding to the extracellular domain of PD-1 receptor blocks the interaction with both PD-L1 and PD\u2011L2 ligands, inhibiting T-cell proliferation and cytokine production. Upregulation of PD-1 ligands occurs in some tumours and signaling through this pathway can contribute to inhibition of active T-cell immune surveillance of tumours.<sup>3<\/sup><\/p>\n<p>TEVIMBRA is the foundational asset of BeOne\u2019s solid tumour portfolio. The global TEVIMBRA clinical development program includes almost 14,000 patients enrolled to date in 35 countries and regions across 70 trials, including 22 registration-enabling studies. For more information, please consult the TEVIMBRAProduct Monograph located at\u00a0<a href=\"\/en\/wp-content\/uploads\/sites\/3\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/beonemedicines.ca\/wp-content\/uploads\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf<\/a>.<\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                                <section class=\"section anim fadeInUp no-popup\">\r\n                            <!-- <section class=\"section anim fadeInUp no-popup\" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    <div class=\"sec-subheading\">\r\n                                                <h4>IMPORTANT SAFETY INFORMATION<\/h4>\r\n                                            <\/div>\r\n                                                                                    \r\n                                            <div><p><strong>Indications &amp; Clinical Use:<\/strong><\/p>\n<p>TEVIMBRA (tislelizumab for injection) in combination with gemcitabine and cisplatin is indicated for the first-line treatment of adult patients with recurrent or metastatic nasopharyngeal carcinoma (NPC).<\/p>\n<p><strong>Pediatrics (&lt;18 years of age):<\/strong><\/p>\n<p>No data are available; therefore, Health Canada has not authorized an indication for pediatric use.<\/p>\n<p><strong>Geriatrics (\u226565 years of age):<\/strong><\/p>\n<p>Based on population pharmacokinetic (PK) analysis, no clinically relevant differences in the PK of\u00a0 TEVIMBRA were observed between patients aged &lt;65 years, patients aged between 65 and 75 years, and patients aged &gt;75 years. Limited safety and efficacy information is available for TEVIMBRA in NPC\u00a0 patients \u2265 65 years.<\/p>\n<p><strong>Contraindications:<\/strong><\/p>\n<p>TEVIMBRA is contraindicated in patients who are hypersensitive to this drug (tislelizumab) or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container.<\/p>\n<p><strong>Serious Warnings and Precautions:<\/strong><\/p>\n<p><strong><u>Immune-mediated adverse reactions:<\/u><\/strong>\u00a0TEVIMBRA may cause severe and fatal immune-mediated adverse reactions, in any organ system or tissue, including: colitis, endocrinopathies, hepatitis, myocarditis, myositis, nephritis with renal dysfunction, organ transplant rejection, pancreatitis, pneumonitis, and severe cutaneous adverse reactions (SCARS e.g., Steven\u2019s Johnson Syndrome and Toxic Epidermal Necrolysis).<\/p>\n<p><strong><u>Infusion-related reactions:<\/u><\/strong>\u00a0TEVIMBRA can cause severe or life-threatening infusion-related reactions including hypersensitivity and anaphylaxis.<\/p>\n<p><strong><u>Patients receiving allogenic hematopoietic stem cell transplantation (HSCT):<\/u><\/strong>\u00a0Fatal and other serious complications can occur in patients receiving HSCT before or after being treated with a PD-1\/PD-L1 blocking antibody.<\/p>\n<p><strong>Other Relevant Warnings and Precautions:<\/strong><\/p>\n<ul class=\"wp-block-list saftey-list has-dark-blue-color has-text-color has-link-color has-medium-font-size wp-elements-2609e1b0ba46957205dbb13db09055e5\">\n<li>Immune-related pneumonitis: Monitor for signs and symptoms of pneumonitis. Suspected pneumonitis should be evaluated with radiographic imaging.<\/li>\n<li>Immune-related hepatitis: Monitor for signs and symptoms of hepatitis and changes in liver function with liver function tests.<\/li>\n<li>Immune-related skin reactions: Monitor for signs and symptoms of suspected skin reactions and exclude other causes.<\/li>\n<li>Immune-related colitis: Monitor for signs and symptoms of colitis.<\/li>\n<li>Thyroid disorders: Monitor for changes in thyroid function and clinical signs and symptoms of thyroid disorders.<\/li>\n<li>Adrenal insufficiency: Monitor for signs and symptoms of adrenal insufficiency.<\/li>\n<li>Hypophysitis\/hypopituitarism: Monitor for signs and symptoms of hypophysitis\/hypopituitarism.<\/li>\n<li>Diabetes mellitus: Monitor for hyperglycemia or other signs and symptoms of diabetes.<\/li>\n<li>Immune-related nephritis with renal dysfunction: Monitor for changes in renal function and exclude other causes of renal dysfunction.<\/li>\n<li>Other immune-related adverse reactions: myositis, myocarditis, arthritis, polymyalgia rheumatica, pericarditis, immune thrombocytopenia, encephalitis, myasthenia gravis, Sjogren\u2019s syndrome, Guillain-Barr\u00e9 syndrome, and hemophagocytic lymphohistiocytosis (HLH).<\/li>\n<li>Solid organ transplant rejection: Consider benefit of treatment with TEVIMBRA vs. risk of possible organ rejection.<\/li>\n<li>Complications of allogenic HSCT: Follow patients closely for evidence of transplant-related complications.<\/li>\n<li>Infusion-related reactions: monitor for signs and symptoms of infusion-related reactions.<\/li>\n<li>Monitoring and laboratory tests: Monitor liver, renal, pituitary, adrenal, and thyroid function prior to initiation and as indicated based on clinical evaluation.<\/li>\n<li>Fertility: No data on the effects of TEVIMBRA on fertility in humans are available.<\/li>\n<li>Contraception: Advise sexually active women of reproductive potential to use effective contraception during treatment and for at least 4 months after the last dose of TEVIMBRA.<\/li>\n<li>Teratogenic risk: Advise women of the potential hazard to a fetus and to avoid becoming pregnant during treatment and for at least 4 months after the last dose of TEVIMBRA.<\/li>\n<li>Breastfeeding: Advise lactating women not to breastfeed during treatment with TEVIMBRA and for at least 4 months after the last dose.<\/li>\n<\/ul>\n<p>&nbsp;<\/p>\n<p><strong>For More Information:<\/strong><\/p>\n<p>Please consult the TEVIMBRA Product Monograph at\u00a0<a href=\"\/en\/wp-content\/uploads\/sites\/3\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/beonemedicines.ca\/wp-content\/uploads\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf<\/a>\u00a0for important information relating to adverse reactions, drug interactions, and dosing information, which have not been discussed in this piece. The Product Monograph is also available by calling 1-877-828-5598.<\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                                <section class=\"section anim fadeInUp \">\r\n                            <!-- <section class=\"section anim fadeInUp \" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    <div class=\"sec-subheading\">\r\n                                                <h4>About BeOne Medicines<\/h4>\r\n                                            <\/div>\r\n                                                                                    \r\n                                            <div><p>BeOne Medicines is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more accessible to cancer patients worldwide. With a portfolio spanning hematology and solid tumours, BeOne is expediting the development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. With a growing global team of nearly 12,000 colleagues spanning six continents, the Company is committed to radically improving access to medicines for far more patients who need them. To learn more about BeOne, please visit\u00a0<a href=\"https:\/\/www.beonemedicines.ca\/\">www.beonemedicines.ca<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.linkedin.com\/company\/beonemedicines\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/x.com\/BeOneMedicines\">X<\/a>,\u00a0<a href=\"https:\/\/www.facebook.com\/BeOneMeds\">Facebook<\/a>\u00a0and\u00a0<a href=\"https:\/\/www.instagram.com\/beonemedicines\/\">Instagram<\/a>.<\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                                <section class=\"section anim fadeInUp no-popup\">\r\n                            <!-- <section class=\"section anim fadeInUp no-popup\" > -->\r\n                                <div class=\"sec-header\">\r\n                                    <div class=\"sec-head\">\r\n                                                                                                                    <\/div>\r\n                                    <div class=\"sec-body\">\r\n                                                                                    <div class=\"sec-subheading\">\r\n                                                <h4>Forward Looking Statement<\/h4>\r\n                                            <\/div>\r\n                                                                                    \r\n                                            <div><p>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws, including statements regarding BeOne\u2019s plans, commitments, aspirations and goals under the caption \u201cAbout BeOne.\u201d Actual results may differ materially from those indicated in the forward-looking statements as a result of various important factors, including BeOne\u2019s ability to demonstrate the efficacy and safety of its drug candidates; the clinical results for its drug candidates, which may not support further development or marketing approval; actions of regulatory agencies, which may affect the initiation, timing and progress of clinical trials and marketing approval; BeOne\u2019s ability to achieve commercial success for its marketed medicines and drug candidates, if approved; BeOne\u2019s ability to obtain and maintain protection of intellectual property for its medicines and technology; BeOne\u2019s reliance on third parties to conduct drug development, manufacturing, commercialization, and other services; BeOne\u2019s limited experience in obtaining regulatory approvals and commercializing pharmaceutical products; BeOne\u2019s ability to obtain additional funding for operations and to complete the development of its drug candidates and achieve and maintain profitability; and those risks more fully discussed in the section entitled \u201cRisk Factors\u201d in BeOne\u2019s most recent quarterly or annual report, as well as discussions of potential risks, uncertainties, and other important factors in BeOne\u2019s subsequent filings with the U.S. Securities and Exchange Commission. All information in this press release is as of the date of this press release, and BeOne undertakes no duty to update such information unless required by law.<\/p>\n<p>&nbsp;<\/p>\n<p><strong>Investor Contact<\/strong><\/p>\n<p>Liza Heapes<br \/>\n+1 857-302-5663<br \/>\n<a href=\"mailto:ir@beonemed.com\">ir@beonemed.com<\/a><\/p>\n<p>&nbsp;<\/p>\n<p><strong>Media Contact<\/strong><\/p>\n<p>Kyle Blankenship<br \/>\n+ 667-351-5176<br \/>\n<a href=\"mailto:media@beonemed.com\">media@beonemed.com<\/a><\/p>\n<p>&nbsp;<\/p>\n<p>To access BeOne media resources, please visit our <a href=\"https:\/\/beonemedicines.com\/newsroom\/\">Newsroom<\/a>.<\/p>\n<hr class=\"wp-block-separator has-alpha-channel-opacity\" \/>\n<p id=\"_ednref1\"><sup>1<\/sup>\u00a0The Canadian Cancer Society.\u00a0What is nasopharyngeal cancer? Available at:\u00a0<a href=\"https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/nasopharyngeal\/what-is-nasopharyngeal-cancer\">https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/nasopharyngeal\/what-is-nasopharyngeal-cancer<\/a>?<\/p>\n<p id=\"_ednref2\"><sup>2<\/sup>\u00a0Spreafico A,\u00a0Winquist E, Ho C, O\u2019Sullivan B, Bouganim N, Chua N, Doucette S, Siu L, Hao D. A Canadian Perspective on Systemic Therapy for Recurrent or Metastatic Nasopharyngeal Carcinoma, Review. Current Oncology, 2025 Jan 17;32(1):48.\u00a0<a href=\"https:\/\/can01.safelinks.protection.outlook.com\/?url=https%3A%2F%2Fdoi.org%2F10.3390%2Fcurroncol32010048&amp;data=05%7C02%7Cryan%40kobayashi.ca%7Ca791cab45bc64f9068af08de421f1090%7Ceeebb00b0d3d48f5af695c5c10f7b5b1%7C0%7C0%7C639020898377605460%7CUnknown%7CTWFpbGZsb3d8eyJFbXB0eU1hcGkiOnRydWUsIlYiOiIwLjAuMDAwMCIsIlAiOiJXaW4zMiIsIkFOIjoiTWFpbCIsIldUIjoyfQ%3D%3D%7C0%7C%7C%7C&amp;sdata=lX5EooVeu2UQ9V4XIAMzHcPkNy2rlzYh3mTvuadgm4Q%3D&amp;reserved=0\" target=\"_blank\" rel=\"noreferrer noopener\">https:\/\/doi.org\/10.3390\/curroncol32010048<\/a>\u00a0PMID: 39851964 PMCID: PMC11763457<\/p>\n<p id=\"_ednref3\"><sup>3<\/sup>\u00a0Product Monograph\u00a0<a href=\"\/en\/wp-content\/uploads\/sites\/3\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf\" target=\"_blank\" rel=\"noopener\">https:\/\/beonemedicines.ca\/wp-content\/uploads\/2025\/12\/1.3.1-TEVIMBRA-PM-NPC-Dec-18-2025.pdf<\/a><\/p>\n<p id=\"_ednref4\"><sup>4<\/sup>\u00a0Wei, X., Chen, B., Wang, Z., et al. (2024). Nasopharyngeal cancer risk assessment by country or region worldwide from 1990 to 2019. BMC Public Health, 24, 1931.\u00a0<a href=\"https:\/\/doi.org\/10.1186\/s12889-024-19228-9\">Https:\/\/doi.org\/10.1186\/s12889-024-19228-9<\/a><\/p>\n<p id=\"_ednref5\"><sup>5<\/sup>\u00a0Canadian Cancer Society. (2025). Head and neck cancer statistics (includes nasopharyngeal cancer; Canada 2025 estimates). Retrieved from\u00a0<a href=\"https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/nasopharyngeal\/statistics\">https:\/\/cancer.ca\/en\/cancer-information\/cancer-types\/nasopharyngeal\/statistics<\/a><\/p>\n<\/div>\r\n                                                                            <\/div>\r\n                                    \r\n                                                                             <!-- <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px;\r\n                                             }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: ;\r\n                                            }\r\n                                         <\/style> -->\r\n                                                                             <style>\r\n                                            .after-buttons {\r\n                                                display: flex; gap: 30px; flex-wrap: wrap;\r\n                                            }\r\n\r\n                                            .after-buttons a {\r\n                                                flex: 0 1 auto;\r\n                                            }\r\n\r\n                                            .after-buttons.multiple > div {\r\n                                                flex: 0 1 calc(50% - 30px);\r\n                                            }\r\n                                        <\/style>\r\n                                     \r\n                                    \r\n                                    <div class=\"after-buttons \">\r\n                                                                            <\/div>\r\n                                <\/div>\t\r\n                            <\/section>\r\n                                    <\/div>\r\n                \r\n            <\/div>\r\n            <div class=\"col-md-4 col-lg-3\">\r\n                \r\n            <\/div> \r\n        <\/div>\r\n    <\/div>\r\n<\/section>\r\n<!-- Copy block -->\r\n","protected":false},"featured_media":0,"template":"","meta":{"_acf_changed":true},"class_list":["post-24287","pressreleases","type-pressreleases","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN<\/title>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN\" \/>\n<meta property=\"og:url\" content=\"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/\" \/>\n<meta property=\"og:site_name\" content=\"BeOne Medicines EN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-23T16:20:43+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/pressreleases\\\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\\\/\",\"url\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/pressreleases\\\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\\\/\",\"name\":\"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/#website\"},\"datePublished\":\"2025-12-23T16:16:26+00:00\",\"dateModified\":\"2025-12-23T16:20:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/pressreleases\\\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/pressreleases\\\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/pressreleases\\\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/\",\"name\":\"BeOne Medicines EN\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/beonemedicines.ca\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN","robots":{"index":"noindex","follow":"follow"},"og_locale":"en_US","og_type":"article","og_title":"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN","og_url":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/","og_site_name":"BeOne Medicines EN","article_modified_time":"2025-12-23T16:20:43+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/","url":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/","name":"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma - BeOne Medicines EN","isPartOf":{"@id":"https:\/\/beonemedicines.ca\/en\/#website"},"datePublished":"2025-12-23T16:16:26+00:00","dateModified":"2025-12-23T16:20:43+00:00","breadcrumb":{"@id":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/beonemedicines.ca\/en\/pressreleases\/health-canada-approves-tevimbra-tislelizumab-for-injection-in-combination-with-gemcitabine-and-cisplatin-for-the-first-line-treatment-of-adult-patients-with-recurrent-or-metastatic-nasopharyng\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/beonemedicines.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Health Canada Approves TEVIMBRA\u00ae (tislelizumab for injection) in Combination with Gemcitabine and Cisplatin for the First-Line Treatment of Adult Patients with Recurrent or Metastatic Nasopharyngeal Carcinoma"}]},{"@type":"WebSite","@id":"https:\/\/beonemedicines.ca\/en\/#website","url":"https:\/\/beonemedicines.ca\/en\/","name":"BeOne Medicines EN","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/beonemedicines.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/beonemedicines.ca\/en\/wp-json\/wp\/v2\/pressreleases\/24287","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedicines.ca\/en\/wp-json\/wp\/v2\/pressreleases"}],"about":[{"href":"https:\/\/beonemedicines.ca\/en\/wp-json\/wp\/v2\/types\/pressreleases"}],"wp:attachment":[{"href":"https:\/\/beonemedicines.ca\/en\/wp-json\/wp\/v2\/media?parent=24287"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}